TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy

Recent studies have suggested that activation of the EGFR pathway leads to malignant transformation only if the p53 protein is inactivated. Therefore, we evaluated the impact of TP53 mutations on cetuximab-based chemotherapy (CT) sensitivity in combination with KRAS mutations that have been associat...

Descripción completa

Detalles Bibliográficos
Autores principales: Oden-Gangloff, A, Di Fiore, F, Bibeau, F, Lamy, A, Bougeard, G, Charbonnier, F, Blanchard, F, Tougeron, D, Ychou, M, Boissière, F, Le Pessot, F, Sabourin, J-C, Tuech, J-J, Michel, P, Frebourg, T
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2009
Materias:
Molecular Diagnostics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676556/
https://www.ncbi.nlm.nih.gov/pubmed/19367287
http://dx.doi.org/10.1038/sj.bjc.6605008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676556/
https://www.ncbi.nlm.nih.gov/pubmed/19367287
http://dx.doi.org/10.1038/sj.bjc.6605008

Ejemplares similares